New and Underutilized Vaccines Indian Medical PG Practice Questions and MCQs
Practice Indian Medical PG questions for New and Underutilized Vaccines. These multiple choice questions (MCQs) cover important concepts and help you prepare for your exams.
New and Underutilized Vaccines Indian Medical PG Question 1: True about polioviruses is -
- A. Spastic paralysis
- B. Most cases are symptomatic
- C. Historically, intramuscular injections during the incubation period were thought to increase paralysis risk.
- D. Inactivated polio vaccine (IPV) is part of the routine immunization schedule for children. (Correct Answer)
New and Underutilized Vaccines Explanation: ***Inactivated polio vaccine (IPV) is part of the routine immunization schedule for children.***
- **IPV is currently included** in India's Universal Immunization Programme (UIP) and is the standard for routine childhood immunization globally.
- IPV is **safe and highly effective** at preventing paralytic polio without the risk of vaccine-associated paralytic polio (VAPP).
- This is the **most current and directly applicable** statement about poliovirus vaccination practices.
*Spastic paralysis*
- Poliovirus causes **flaccid paralysis**, not spastic paralysis.
- This results from destruction of **anterior horn cells** in the spinal cord, leading to lower motor neuron damage and loss of muscle tone.
*Most cases are symptomatic*
- This is **incorrect**. Approximately **95% of poliovirus infections are asymptomatic** or cause only mild, non-specific symptoms.
- Only **<1% of infections** progress to paralytic poliomyelitis.
*Historically, intramuscular injections during the incubation period were thought to increase paralysis risk*
- This statement is **historically accurate** (phenomenon called "provocation poliomyelitis").
- However, this is a **historical observation** from the pre-vaccine era, whereas the correct answer reflects **current immunization practice**.
- The question asks what is "true about polioviruses," making the current vaccination practice more relevant than historical epidemiological observations.
New and Underutilized Vaccines Indian Medical PG Question 2: True about HPV vaccination -
- A. Efficacy > 70% for cervical cancer (Correct Answer)
- B. Two types are available in market
- C. Given in women age group 20-40 years
- D. Primary dose consists of 2 doses
New and Underutilized Vaccines Explanation: ***Efficacy > 70% for cervical cancer***
- HPV vaccines are highly effective, with **bivalent, quadrivalent, and nonavalent vaccines** demonstrating remarkable efficacy against **high-grade cervical lesions** and **cervical cancer**, often exceeding 70% and even up to 90% against types 16 and 18.
- The primary goal of HPV vaccination is to **prevent cervical cancer** caused by high-risk HPV types.
*Two types are available in market*
- This statement is incorrect; currently, there are **three types of HPV vaccines** available globally: **bivalent (targeting HPV 16/18)**, **quadrivalent (targeting HPV 6/11/16/18)**, and **nonavalent (targeting 9 HPV types)**.
- The availability of vaccine types may vary by region, but more than two formulations exist worldwide.
*Given in women age group 20-40 years*
- HPV vaccination is primarily recommended for **adolescents and young adults**, typically starting around **age 11-12 years**, with catch-up vaccinations recommended up to **age 26 years** for those not previously vaccinated.
- While some guidelines extend recommendations for individuals up to **age 45** after shared clinical decision-making, it is not routinely given across the broad 20-40 age group as a primary target.
*Primary dose consists of 2 doses*
- This statement is **incomplete and not universally true**; the HPV vaccination schedule **varies by age at initiation**.
- For adolescents aged **9-14 years**, a **two-dose schedule** (0, 6-12 months) is recommended.
- For individuals aged **15 years and older**, a **three-dose schedule** (0, 1-2, 6 months) is required for complete protection.
- Since the schedule is age-dependent and not uniformly 2 doses, this statement cannot be considered fully correct.
New and Underutilized Vaccines Indian Medical PG Question 3: True about rotavirus vaccine:
- A. Given orally (Correct Answer)
- B. Killed vaccine
- C. Should be given before 5 years
- D. Given subcutaneous
New and Underutilized Vaccines Explanation: ***Given orally***
- Rotavirus vaccines are **live attenuated vaccines** administered orally to stimulate localized immunity in the gastrointestinal tract.
- This oral route is crucial for inducing **mucosal immunity**, which is important for protection against rotavirus infection.
*Killed vaccine*
- The rotavirus vaccine is an **attenuated live vaccine**, meaning it contains weakened forms of the virus, not killed ones.
- Live attenuated vaccines generally provide a **stronger and longer-lasting immune response** compared to killed vaccines.
*Should be given before 5 years*
- The rotavirus vaccine series is recommended to be completed in **infancy**, typically before 8 months of age, depending on the specific vaccine brand and schedule.
- Giving the vaccine at too old an age increases the (still very small) risk of **intussusception** and a lack of efficacy.
*Given subcutaneous*
- Rotavirus vaccines are administered by the **oral route**, not subcutaneously.
- The **subcutaneous route** is used for various other vaccines, but not for rotavirus.
New and Underutilized Vaccines Indian Medical PG Question 4: Assertion: VZV vaccine is live attenuated. Reason: It cannot be given to immunocompromised patients.
- A. Both true, reason doesn't explain assertion
- B. Assertion true, reason false
- C. Assertion false, reason true
- D. Both true, reason explains assertion (Correct Answer)
New and Underutilized Vaccines Explanation: ***Both true, reason explains assertion***
- The **VZV (varicella-zoster virus) vaccine** is indeed a **live attenuated vaccine** containing weakened virus - the assertion is **TRUE**
- It **cannot be given to immunocompromised patients** due to risk of vaccine-strain disease - the reason is **TRUE**
- The reason **directly explains the assertion**: BECAUSE the vaccine is live attenuated, it poses infection risk and therefore cannot be used in immunocompromised individuals
- The **causal relationship** is clear: live attenuated nature → contraindication in immunocompromised patients
*Both true, reason doesn't explain assertion*
- While both statements are factually true, this option would only be correct if the reason was unrelated to the assertion
- However, the reason **directly explains WHY** the live attenuated nature is clinically significant
- The contraindication is a **direct consequence** of the vaccine being live attenuated, so the reason does explain the assertion
*Assertion true, reason false*
- The assertion is true (VZV vaccine is live attenuated)
- However, the reason is also **TRUE** - live attenuated vaccines are indeed contraindicated in immunocompromised patients due to risk of disseminated vaccine-strain infection
- Since both statements are true, this option is incorrect
*Assertion false, reason true*
- The assertion is **TRUE**, not false - VZV vaccine (Varivax, Zostavax) is a **live attenuated vaccine** containing the Oka strain
- This option incorrectly claims the assertion is false
- Since the assertion is factually correct, this option cannot be right
New and Underutilized Vaccines Indian Medical PG Question 5: Typhoid Vi polysaccharide vaccine is usually administered in children above the age of :
- A. 1 year 6 months
- B. 1 year
- C. 2 years (Correct Answer)
- D. 6 months
New and Underutilized Vaccines Explanation: ***2 years***
- The **Typhoid Vi polysaccharide vaccine** is generally recommended for children starting at **2 years of age** because younger children may have a suboptimal immune response to polysaccharide vaccines.
- This age limit helps ensure better **immunogenicity** and protection in the vaccinated child.
*1 year 6 months*
- While some vaccines are given around this age, the **Typhoid Vi polysaccharide vaccine** is not typically administered at **1 year 6 months** due to concerns about vaccine efficacy in very young children.
- Administering it before **2 years** may lead to a less robust and protective immune response.
*1 year*
- **One-year-olds** generally do not respond as effectively to **polysaccharide vaccines** as older children.
- The immune system matures, and the response to this specific type of vaccine improves significantly after the age of **2 years**.
*6 months*
- Vaccinating an infant at **6 months** with the **Typhoid Vi polysaccharide vaccine** is not recommended.
- The immune system of an infant at this age is still developing and would likely produce an inadequate and **short-lived immune response** to this vaccine.
New and Underutilized Vaccines Indian Medical PG Question 6: Which of the following statements about HPV vaccination is true?
- A. It is given to women aged 20-40 years.
- B. The primary dose consists of 2 doses.
- C. It has an efficacy greater than 70% for cervical cancer. (Correct Answer)
- D. There are two types available in the market.
New and Underutilized Vaccines Explanation: ***It has an efficacy greater than 70% for cervical cancer.***
- HPV vaccines are highly effective in preventing **HPV infections**, which are the primary cause of cervical cancer. Studies show they have an efficacy of **over 70%** (and often much higher for certain strains) in preventing cervical precancers and cancers.
- The vaccine works by inducing an immune response to the **HPV L1 capsid protein**, which prevents the virus from infecting cells.
*It is given to women aged 20-40 years.*
- The primary target group for HPV vaccination is **adolescents**, typically aged 9-14 years, before potential exposure to the virus.
- While catch-up vaccination may be recommended for young adults up to age 26, routine vaccination in women aged 20-40 years is **less common and less effective** due to likely prior exposure.
*The primary dose consists of 2 doses.*
- For individuals initiating vaccination before their 15th birthday, the primary dose schedule consists of **2 doses**.
- For individuals 15 years and older, a **3-dose schedule** is typically recommended.
*There are two types available in the market.*
- Currently, there are **three types** of HPV vaccines available globally: bivalent (targeting HPV 16, 18), quadrivalent (targeting HPV 6, 11, 16, 18), and **nonavalent (targeting HPV 6, 11, 16, 18, 31, 33, 45, 52, 58)**.
- The specific types available in a particular market may vary, but globally, there are more than two.
New and Underutilized Vaccines Indian Medical PG Question 7: For which of the following is PPV-23 most beneficial:
- A. Child less than 2 years
- B. Sickle cell anemia patient (Correct Answer)
- C. Cystic fibrosis patient
- D. Patient with recurrent rhinitis and sinusitis
New and Underutilized Vaccines Explanation: ***Sickle cell anemia patient***
- Individuals with **sickle cell anemia** are at a **high risk of invasive pneumococcal disease** due to functional asplenia, making PPV-23 highly beneficial for them.
- The **PPV-23 vaccine** targets 23 serotypes of *Streptococcus pneumoniae* and is recommended for those aged 2 years and older with certain chronic medical conditions, including sickle cell disease.
- This is one of the **strongest indications** for PPV-23 due to the severe immunocompromise from splenic dysfunction.
*Child less than 2 years*
- The **polysaccharide vaccines** like PPV-23 are generally **not effective in children younger than 2 years** as their immature immune system does not respond well to polysaccharide antigens.
- For children in this age group, the **pneumococcal conjugate vaccine (PCV13)**, which elicits a T-cell-dependent immune response, is recommended.
*Cystic fibrosis patient*
- While patients with **cystic fibrosis** are at increased risk for respiratory infections, the primary pathogens are typically *Pseudomonas aeruginosa* and *Staphylococcus aureus*, not *Streptococcus pneumoniae*.
- Although pneumococcal vaccination (including PPV-23) is generally recommended for individuals with chronic lung disease, it is **not as specifically indicated or beneficial as for sickle cell patients** who demonstrate profoundly impaired splenic function.
*Patient with recurrent rhinitis and sinusitis*
- **Recurrent rhinitis and sinusitis** are commonly caused by **viral infections**, allergies, or anatomical abnormalities, not typically by serious invasive pneumococcal disease against which PPV-23 offers protection.
- While some episodes might involve *Streptococcus pneumoniae*, this condition does not place a patient in the same **high-risk category for severe, invasive pneumococcal infections** that would mandate PPV-23 vaccination as a primary intervention.
New and Underutilized Vaccines Indian Medical PG Question 8: Live vaccines are contraindicated in all except:
- A. Breastfeeding mothers (Correct Answer)
- B. Pregnant women
- C. Immunocompromised patients
- D. Patients on high-dose immunosuppressants
New and Underutilized Vaccines Explanation: ***Breastfeeding mothers***
- Live vaccines are generally **safe for breastfeeding mothers** and their infants, as the vaccine viruses are not typically excreted in breast milk in levels that can infect the infant.
- The benefits of vaccinating the mother outweigh any theoretical risks, and it can provide **passive immunity** to the infant through antibodies in breast milk.
*Pregnant women*
- Live vaccines are **contraindicated during pregnancy** due to the theoretical risk of transmitting the attenuated virus to the fetus and causing congenital infection.
- Examples include **MMR** and **varicella vaccines**, which should be administered before or after pregnancy.
*Immunocompromised patients*
- Live vaccines are **contraindicated** in individuals with compromised immune systems due to the risk of the attenuated vaccine virus causing **disseminated infection** or severe disease.
- This includes patients with **HIV/AIDS** (with low CD4 counts), congenital immunodeficiencies, and those undergoing active cancer treatment.
*Patients on high-dose immunosuppressants*
- These patients are considered **immunocompromised**, and live vaccines are **contraindicated** because their suppressed immune system may not be able to effectively control the attenuated vaccine virus, leading to severe infection.
- Examples of such medications include high-dose corticosteroids, chemotherapy agents, and biologics that target immune cells.
New and Underutilized Vaccines Indian Medical PG Question 9: All are correct about the vaccine shown except:
- A. Bivalent
- B. Recombinant vaccine
- C. Recommended in all women in age group 25-45 years (Correct Answer)
- D. 3 dosages
New and Underutilized Vaccines Explanation: ***Recommended in all women in age group 25-45 years***
- While Cervarix (HPV vaccine) is important for preventing **cervical cancer**, routine vaccination is primarily recommended for adolescents and young adults (up to age 26).
- Catch-up vaccination for women aged 27-45 years is a shared clinical decision, not a universal recommendation for "all women" in that age group.
*Bivalent*
- **Cervarix** is a **bivalent vaccine**, meaning it protects against two HPV types: HPV-16 and HPV-18.
- These two types are responsible for the majority of **cervical cancers**.
*Recombinant vaccine*
- HPV vaccines, including Cervarix, are **recombinant vaccines**.
- They are specifically **virus-like particle (VLP) vaccines**, which means they contain no viral DNA and cannot cause infection.
*3 dosages*
- When initially introduced, Cervarix was administered in a **3-dose schedule** (0, 1-2, and 6 months).
- For adolescents initiating vaccination before age 15, a 2-dose schedule is now often recommended, but a 3-dose schedule remains standard for older individuals or those with certain immunocompromising conditions.
New and Underutilized Vaccines Indian Medical PG Question 10: Due to a measles outbreak in a community, a medical officer decided to immunize a child aged seven months with measles vaccine. When should the next measles vaccine be administered?
- A. Not required
- B. When the child completes nine months of age (Correct Answer)
- C. When the child completes fifteen months of age
- D. After four weeks
New and Underutilized Vaccines Explanation: ***When the child completes nine months of age***
- A measles vaccine given at **seven months during an outbreak** is considered a **zero-dose** or **early dose** and does NOT replace the routine immunization schedule.
- According to the **Indian National Immunization Schedule**, the routine first dose of measles vaccine (MR vaccine) is given at **9 months of age**, regardless of whether an earlier outbreak dose was administered.
- Vaccines given before 9 months have **reduced efficacy** due to interference from maternal antibodies, making the 9-month dose essential for adequate seroconversion.
- After the 9-month dose, a second dose is given at **16-24 months** as per routine schedule.
*When the child completes fifteen months of age*
- While 15-18 months is appropriate timing for the **second dose** of measles vaccine in the routine schedule, it is not the immediate next dose after a 7-month outbreak vaccination.
- The child still requires the **routine 9-month dose first**, followed by the second dose at 16-24 months.
- Skipping the 9-month dose and going directly to 15 months would leave a prolonged gap without adequate protection.
*Not required*
- This is **incorrect** because early doses given before 9 months are considered zero-doses and do not provide reliable long-term immunity.
- The routine schedule **must still be followed** to ensure proper immunization, starting with the 9-month dose.
*After four weeks*
- A four-week interval after the 7-month dose is **too short** and not recommended in immunization guidelines.
- There is **no indication** for such an early repeat dose; the child should wait until the routine 9-month schedule for the next dose.
More New and Underutilized Vaccines Indian Medical PG questions available in the OnCourse app. Practice MCQs, flashcards, and get detailed explanations.
